Search
Resiquimod
go.drugbank.com/drugs/DB06530InvestigationalIt is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response. It is a type of imidazoquinoline and a type of immunomodulator. … A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help them kill tumor cells.
Categories: Heterocyclic Compounds, 1-RingPazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnCatumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … It is currently available under the brand name Removab.
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalPeramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet)Casopitant
go.drugbank.com/drugs/DB06634InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Neurokinin-1 Receptor AntagonistsArbekacin
go.drugbank.com/drugs/DB06696InvestigationalOften used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexDexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. … The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181].
Categories: Heterocyclic Compounds, 1-RingSynonyms: methyl (R)-phenyl[(R)-piperidin-2-yl]acetate, D-TMPIobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalIodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
Salts: Iobenguane I 123, Iobenguane I 131Categories: Compounds used in a research, industrial, or household setting